抗gp210抗体在原发性胆汁性胆管炎中的产生机制与检测价值

张继红; 李素领

doi:10.3969/j.issn.1001-5256.2022.06.041

抗gp210抗体在原发性胆汁性胆管炎中的产生机制与检测价值

DOI: 10.3969/j.issn.1001-5256.2022.06.041

张继红¹,
李素领^2, , ,

1.
河南中医药大学第一临床医学院，郑州 450000
2.
河南中医药大学第一附属医院脾胃肝胆科，郑州 450000

基金项目:

河南省中医药科学研究专项课题 (20-21ZY1011)

利益冲突声明：所有作者均声明不存在利益冲突。

作者贡献声明：张继红负责拟定提纲、收集文献及撰写论文；李素领负责指导撰写论文、修改论文，并最后定稿。

详细信息

通信作者:
李素领，hk-lsl@163.com

计量
- 文章访问数: 797
- HTML全文浏览量: 469
- PDF下载量: 66
- 被引次数: 0
出版历程
- 收稿日期: 2021-09-26
- 录用日期: 2021-10-28
- 出版日期: 2022-06-20

Production mechanism and detection value of anti-gp210 antibody in primary biliary cholangitis

Jihong ZHANG¹,
Suling LI^{2
, ,
,}

1.
The First Clinical Medical College of Henan University of Chinese Medicine, Zhengzhou 450000, China
2.
Department of Hepatology and Spleen-Stomach, The First Affiliated Hospital of Henan University of Chinese Medicine, Zhengzhou 450000, China

Research funding:

Special Subject of Scientific Research on Traditional Chinese Medicine in Henan Province (20-21ZY1011)

More Information

Corresponding author: LI Suling, hk-lsl@163.com(ORCID: 0000-0002-5211-1330)

摘要

摘要: 原发性胆汁性胆管炎(PBC)是自身免疫性肝病之一，多数患者早期无明显临床表现，出现症状已至中晚期，尽早明确诊断及评估预后是非常必要的。抗gp210抗体对于诊断PBC及预测疾病进展有重要价值，检测该抗体可以优化PBC评分系统。本文总结评述了抗gp210抗体在PBC中的产生机制及检测的具体价值。
- 肝硬化, 胆汁性 /
- 抗体 /
- 诊断 /
- 预后
Abstract: Primary biliary cholangitis (PBC) is one of the autoimmune liver diseases, and most patients have no obvious clinical manifestations in the early stage and have reached the advanced stage when symptoms appear. Therefore, it is necessary to make a confirmed diagnosis and evaluate prognosis as early as possible. Anti-gp210 antibody is of great value in the diagnosis of PBC and the prediction of disease progression, and the detection of anti-gp210 antibody can help to optimize the PBC scoring system. This article reviews the production mechanism and detection value of anti-gp210 antibody in PBC.
- Liver Cirrhosis, Biliary /
- Antibodies /
- Diagnosis /
- Prognosis

HTML全文

参考文献(39)

[1]	BEUERS U, GERSHWIN ME, GISH RG, et al. Changing nomenclature for PBC: From 'cirrhosis' to 'cholangitis'[J]. J Hepatol, 2015, 63(5): 1285-1287. DOI: 10.1016/j.jhep.2015.06.031.
[2]	LINDOR KD, BOWLUS CL, BOYER J, et al. Primary biliary cholangitis: 2018 practice guidance from the American Association for the Study of Liver Diseases[J]. Hepatology, 2019, 69(1): 394-419. DOI: 10.1002/hep.30145.
[3]	GERSHWIN ME, VIERLING JM, TANAKA A, et al. Liver Immunology: principles and practice[M]. Springer Nature, 2020: 335-358.
[4]	ZANDANELL S, STRASSER M, FELDMAN A, et al. Similar clinical outcome of AMA immunoblot-M2-negative compared to immunoblot-positive subjects over six years of follow-up[J]. Postgrad Med, 2021, 133(3): 291-298. DOI: 10.1080/00325481.2021.1885945.
[5]	BEN LAMINE Z, BEN JAZIA I, BEN AHMED M, et al. Anti-gp210 and anti-Sp100 antibodies in primary biliary cholangitis[J]. Arab J Gastroenterol, 2021, 22(4): 316-320. DOI: 10.1016/j.ajg.2021.05.006.
[6]	KOUROUMALIS E, SAMONAKIS D, VOUMVOURAKI A. Biomarkers for primary biliary cholangitis: Current perspectives[J]. Hepat Med, 2018, 10: 43-53. DOI: 10.2147/HMER.S135337.
[7]	QIU F, TANG R, ZUO X, et al. A genome-wide association study identifies six novel risk loci for primary biliary cholangitis[J]. Nat Commun, 2017, 8: 14828. DOI: 10.1038/ncomms14828.
[8]	ZHAO DT, LIAO HY, ZHANG X, et al. Human leucocyte antigen alleles and haplotypes and their associations with antinuclear antibodies features in Chinese patients with primary biliary cirrhosis[J]. Liver Int, 2014, 34(2): 220-226. DOI: 10.1111/liv.12236.
[9]	KEMPINSKA-PODHORODECKA A, SHUMS Z, WASILEWICZ M, et al. TRAF1 gene polymorphism correlates with the titre of Gp210 antibody in patients with primary biliary cirrhosis[J]. Clin Dev Immunol, 2012, 2012: 487521. DOI: 10.1155/2012/487521.
[10]	TANAKA A, LEUNG P, GERSHWIN ME. Pathogen infections and primary biliary cholangitis[J]. Clin Exp Immunol, 2019, 195(1): 25-34. DOI: 10.1111/cei.13198.
[11]	TANAKA A, LEUNG PS, GERSHWIN ME. Environmental basis of primary biliary cholangitis[J]. Exp Biol Med (Maywood), 2018, 243(2): 184-189. DOI: 10.1177/1535370217748893.
[12]	FLOREANI A, LEUNG PS, GERSHWIN ME. Environmental basis of autoimmunity[J]. Clin Rev Allergy Immunol, 2016, 50(3): 287-300. DOI: 10.1007/s12016-015-8493-8.
[13]	SHIMODA S, NAKAMURA M, ISHIBASHI H, et al. Molecular mimicry of mitochondrial and nuclear autoantigens in primary biliary cirrhosis[J]. Gastroenterology, 2003, 124(7): 1915-1925. DOI: 10.1016/s0016-5085(03)00387-1.
[14]	HARUTA I, KIKUCHI K, HASHIMOTO E, et al. Long-term bacterial exposure can trigger nonsuppurative destructive cholangitis associated with multifocal epithelial inflammation[J]. Lab Invest, 2010, 90(4): 577-588. DOI: 10.1038/labinvest.2010.40.
[15]	HARUTA I, KIKUCHI K, NAKAMURA M, et al. Involvement of commensal bacteria may lead to dysregulated inflammatory and autoimmune responses in a mouse model for chronic nonsuppurative destructive cholangitis[J]. J Clin Immunol, 2012, 32(5): 1026-1037. DOI: 10.1007/s10875-012-9712-1.
[16]	TANG R, WEI Y, LI Y, et al. Gut microbial profile is altered in primary biliary cholangitis and partially restored after UDCA therapy[J]. Gut, 2018, 67(3): 534-541. DOI: 10.1136/gutjnl-2016-313332.
[17]	Chinese Society of Hepatology, Chinese Medical Association; Chinese Society of Gastroenterology, Chinese Medical Association; Chinese Society of Infectious Diseases, Chinese Medi-cal Association. Consensus on the diagnosis and management of primary biliary cirrhosis (cholangitis) (2015)[J]. J Clin Hepatol, 2015, 31(12): 1980-1988. DOI: 10.3969/j.issn.1001-5256.2015.12.004. 中华医学会肝病学分会, 中华医学会消化病学分会, 中华医学会感染病学分会. 原发性胆汁性肝硬化(又名原发性胆汁性胆管炎)诊断和治疗共识(2015)[J]. 临床肝胆病杂志, 2015, 31 (12): 1980-1988. DOI: 10.3969/j.issn.1001-5256.2015.12.004.
[18]	SEBODE M, WEILER-NORMANN C, LIWINSKI T, et al. Autoantibodies in autoimmune liver disease-clinical and diagnostic relevance[J]. Front Immunol, 2018, 9: 609. DOI: 10.3389/fimmu.2018.00609.
[19]	European Association for the Study of the Liver. EASL clinical practice guidelines: The diagnosis and management of patients with primary biliary cholangitis[J]. J Hepatol, 2017, 67(1): 145-172. DOI: 10.1016/j.jhep.2017.03.022.
[20]	DANG FT, TANG YM. Diagnostic and prognostic value of autoantibodies in primary biliary cholangitis[J]. J Clin Hepatol, 2020, 36(5): 1164-1166. DOI: 10.3969/j.issn.1001-5256.2020.05.048. 党富涛, 唐映梅. 自身抗体在原发性胆汁性胆管炎中的诊断及预后价值[J]. 临床肝胆病杂志, 2020, 36(5): 1164-1166. DOI: 10.3969/j.issn.1001-5256.2020.05.048.
[21]	RESHETNYAK VI. Primary biliary cirrhosis: Clinical and laboratory criteria for its diagnosis[J]. World J Gastroenterol, 2015, 21(25): 7683-7708. DOI: 10.3748/wjg.v21.i25.7683.
[22]	VALOUR F, DURUPT S, KHENIFER S, et al. Diagnostic value of anti-gp210 antibodies in primary biliary cirrhosis: A case-based review[J]. BMJ Case Rep, 2013, 2013: bcr2013009803. DOI: 10.1136/bcr-2013-009803.
[23]	DENG HM, HU SL, CHEN WX, et al. Meta-analysis of anti-GP210 antibody and anti-SP100 antibody detection for diagnosis of primary biliary cirrhosis[J]. Chin J Hepatol, 2016, 24(1): 62-68. DOI: 10.3760/cma.j.issn.1007-3418.2016.01.012. 邓红梅, 胡世玲, 陈维贤, 等. 抗核孔膜蛋白和抗核体蛋白抗体对原发性胆汁性肝硬化诊断价值的Meta分析[J]. 中华肝脏病杂志, 2016, 24(1): 62-68. DOI: 10.3760/cma.j.issn.1007-3418.2016.01.012.
[24]	ZHANG Q, LIU Z, WU S, et al. Meta-analysis of antinuclear antibodies in the diagnosis of antimitochondrial antibody-negative primary biliary cholangitis[J]. Gastroenterol Res Pract, 2019, 2019: 8959103. DOI: 10.1155/2019/8959103.
[25]	TANAKA A. Current understanding of primary biliary cholangitis[J]. Clin Mol Hepatol, 2021, 27(1): 1-21. DOI: 10.3350/cmh.2020.0028.
[26]	REIG A, NORMAN GL, GARCIA M, et al. Novel anti-hexokinase 1 antibodies are associated with poor prognosis in patients with primary biliary cholangitis[J]. Am J Gastroenterol, 2020, 115(10): 1634-1641. DOI: 10.14309/ajg.0000000000000690.
[27]	NAKAMURA M, KONDO H, TANAKA A, et al. Autoantibody status and histological variables influence biochemical response to treatment and long-term outcomes in Japanese patients with primary biliary cirrhosis[J]. Hepatol Res, 2015, 45(8): 846-855. DOI: 10.1111/hepr.12423.
[28]	GATSELIS NK, ZACHOU K, NORMAN GL, et al. Clinical significance of the fluctuation of primary biliary cirrhosis-related autoantibodies during the course of the disease[J]. Autoimmunity, 2013, 46(7): 471-479. DOI: 10.3109/08916934.2013.801461.
[29]	HUANG C, HAN W, WANG C, et al. Early prognostic utility of Gp210 antibody-positive rate in primary biliary cholangitis: A meta-analysis[J]. Dis Markers, 2019, 2019: 9121207. DOI: 10.1155/2019/9121207.
[30]	WANG J, HU F, HE C, et al. Diagnostic value of anti-gp210 combined with indirect serum markers for predicting histological staging in patients with primary biliary cholangitis[J]. EBioMedicine, 2019, 2019: 1-21.
[31]	HALDAR D, JANMOHAMED A, PLANT T, et al. Antibodies to gp210 and understanding risk in patients with primary biliary cholangitis[J]. Liver Int, 2021, 41(3): 535-544. DOI: 10.1111/liv.14688.
[32]	CRISTOFERI L, GERUSSI A, INVERNIZZI P. Anti-gp210 and other anti-nuclear pore complex autoantibodies in primary biliary cholangitis: What we know and what we should know[J]. Liver Int, 2021, 41(3): 432-435. DOI: 10.1111/liv.14791.
[33]	NAKAMURA M, KOMORI A, ITO M, et al. Predictive role of anti-gp210 and anticentromere antibodies in long-term outcome of primary biliary cirrhosis[J]. Hepatol Res, 2007, 37 (Suppl 3): S412-S419. DOI: 10.1111/j.1872-034X.2007.00244.x.
[34]	NAKAMURA M, KONDO H, MORI T, et al. Anti-gp210 and anti-centromere antibodies are different risk factors for the progression of primary biliary cirrhosis[J]. Hepatology, 2007, 45(1): 118-127. DOI: 10.1002/hep.21472.
[35]	WANG XJ, LIU Y, WANG XB. Biochemical response and integrated traditional Chinese and Western medicine therapy for primary biliary cholangitis[J]. J Clin Hepatol, 2020, 36(1): 26-30. DOI: 10.3969/j.issn.1001-5256.2020.01.004. 王晓静, 刘尧, 王宪波. 原发性胆汁性胆管炎的熊去氧胆酸生化应答预测及中西医结合治疗[J]. 临床肝胆病杂志, 2020, 36(1): 26-30. DOI: 10.3969/j.issn.1001-5256.2020.01.004.
[36]	STURROCK BRH, ROGERS JK, SADLER R, et al. Anti-gp210 and anti-sp100 antibody status and ursodeoxycholic acid response in primary biliary cholangitis[J]. J Gastroenterol Hepatol Res, 2018, 7(6): 2741-2747. DOI: 10.17554/j.issn.2224-3992.2018.07.797.
[37]	LAMMERS WJ, HIRSCHFIELD GM, CORPECHOT C, et al. Development and validation of a scoring system to predict outcomes of patients with primary biliary cirrhosis receiving ursodeoxycholic acid therapy[J]. Gastroenterology, 2015, 149(7): 1804-1812. DOI: 10.1053/j.gastro.2015.07.061.
[38]	CARBONE M, SHARP SJ, FLACK S, et al. The UK-PBC risk scores: Derivation and validation of a scoring system for long-term prediction of end-stage liver disease in primary biliary cholangitis[J]. Hepatology, 2016, 63(3): 930-950. DOI: 10.1002/hep.28017.
[39]	YANG F, YANG Y, WANG Q, et al. The risk predictive values of UK-PBC and GLOBE scoring system in Chinese patients with primary biliary cholangitis: the additional effect of anti-gp210[J]. Aliment Pharmacol Ther, 2017, 45(5): 733-743. DOI: 10.1111/apt.13927.